Neuroprotective role of nanoparticles against Alzheimer's disease

Current Drug Metabolism

Volumn 17, Issue 2, 2016, Pages 142-149

  Obulesu, Magisetty ^a   Jhansilakshmi, Magisetty ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b CENTRAL FOOD TECHNOLOGICAL RESEARCH INSTITUTE   (India)

Author keywords

Alzheimer's disease; Curcumin; Metal chelators; Redox nanoparticles

Indexed keywords

CURCUMIN; DEFEROXAMINE; NANOPARTICLE; NEUROPROTECTIVE AGENT; NITROXIDE DERIVATIVE; PIPERINE; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; ARTICLE; CHELATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SYSTEMIC THERAPY; ANIMAL; DRUG EFFECTS; METABOLISM; OXIDATION REDUCTION REACTION;

ALZHEIMER DISEASE; ANIMALS; HUMANS; NANOPARTICLES; NEUROPROTECTIVE AGENTS; OXIDATION-REDUCTION; REACTIVE OXYGEN SPECIES;

EID: 84958234169     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920021702160114160341     Document Type: Article

References (121)

1. Obulesu, M.; Jhansilakshmi, M. Apoptosis in Alzheimers Disease: An understanding of the physiology, pathology and therapeutic avenues. Neurochem. Res., 2014, 39(12), 2301-2312.
2. Obulesu, M.; Rao, D.M.; Shamasundar, N.M. Studies on genomic DNA stability in aluminium maltolate treated aged New Zealand rabbit: relevan ce to the Alzheimers animal model. J. Clin. Med Res., 2009, 1, 212-218.
3. Obulesu, M.; Rao, D.M. Animal models of Alzheimers disease: an understanding of pathology and therapeutic avenues. Int. J Neurosci., 2010,120, 531-537.
4. Obulesu, M.; Rao, D.M. DNA damage and impairment of DNA repair in Alzheimers disease. Int. J Neurosci., 2010, 120, 397-403.
5. Obulesu, M.; Venu, R.; Somashekhar, R. Lipid peroxidation in Alzheimers Disease: Emphasis on metal mediated neurotoxicity. Acta Neurol. Scand., 2011, 124, 295-301.
6. Obulesu, M.; Somashekhar, R.; Venu, R. Genetics of Alzheimers Disease: Apo E and Presenilins instigated neurodegeneration. Int. J. Neurosci., 2011, 121, 229-236.
7. Yamamoto, Y. Current topics about mild cognitive impairment (MCI). Seishin Shinkeigaku Zasshi, 2011, 113, 584-592.
8. Mufamadi, M.S.; Choonara, Y.E.; Kumar, P.; Modi, G.; Naidoo, D.; Ndesendo, V.M.; du Toit, L.C.; Iyuke, S.E.; Pillay, V. Surfaceengineered nanoliposomes by chelating ligands for modulating the neurotoxicity associated with-amyloid aggregates of Alzheimer's disease. Pharm. Res., 2012, 29, 3075-3089.
9. Urano, Y.; Ochiai, S.; Noguchi, N. Suppression of amyloid- production by 24S-hydroxycholesterol via inhibition of intracellular amyloid precursor protein trafficking. FASEB J., 2013, 27, 4305-4315.
10. Brinton, R.D. A women's health issue: Alzheimers disease and strategies for maintaining cognitive health. Int. J. Fertil. Womens Med. 1999, 44, 174-185.
11. Gozes, I. Neuroprotective peptide drug delivery and development: Potential new therapeutics. Trends Neurosci., 2001, 24, 700-705.
12. Kroll, R.A.; Neuwelt, E.A. Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery, 1998, 42, 1083-1099.
13. Haney, M.J.; Zhao, Y.; Li, S.; Higginbotham, S.M.; Booth, S.L.; Han, H.Y.; Vetro, J.A.; Mosley, R.L.; Kabanov, A.V.; Gendelman, H.E.; Batrakova, E.V. Cell-mediated Transfer of Catalase Nanoparticles from Macrophages to Brain Endothelial and Neural Cells. Nanomedicine (Lond)., 2011, 6, 1215-1230.
14. Gittins, D.I.; Bethell, D.; Schiffrin, D.J.; Nichols, R.J. A nanometre- scale electronic switch consisting of a metal cluster and redoxaddressable groups. Nature, 2000, 408, 67-69.
15. Darroudi, M.; Ahmad, M.B.; Abdullah, A.H.; Ibrahim, N.A. Green synthesis and characterization of gelatin-based and sugar-reduced silver nanoparticles. Int. J. Nanomed., 2011, 6, 569-574.
16. Wise, K.; Brasuel, M. The current state of engineered nanomaterials in consumer goods and waste streams: the need to develop nanoproperty-quantifiable sensors for monitoring engineered nanomaterials. Nanotechnol. Sci. Appl., 2011, 4, 73-86.
17. Ghosh, S.; Patil, S.; Ahire, M.; Kitture, R.; Kale, S.; Pardesi, K.; Cameotra, S.S.; Bellare, J.; Dhavale, D.D.; Jabgunde, A.; Chopade, B.A. Synthesis of silver nanoparticles using Dioscorea bulbifera tuber extract and evaluation of its synergistic potential in combination with antimicrobial agents. Int. J Nanomedicine., 2012, 7, 483-496.
18. 18. Shukla, R.; Chanda, N.; Zambre, A.; Upendran, A.; Katti, K.; Kulkarni, R.R.; Nune, S.K.; Casteel, S.W.; Smith, C.J.; Vimal, J.; Boote, E.; Robertson, J.D; Kan, P.; Engelbrecht, H.; Watkinson, L.D.; Carmack, T.L.; Lever, J.R.; Cutler, C.S.; Caldwell, C.; Kannan, R.; Katti, K.V. Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer. Proc. Natl. Acad. Sci. U.S.A., 2012, 109, 12426-12431.
19. Matson, J.B.; Grubbs, R.H. Synthesis of fluorine-18 functionalized nanoparticles for use as in vivo molecular imaging agents. J. Am. Chem. Soc., 2008, 130, 6731-6733.
20. Kattumuri, V.; Katti, K.; Bhaskaran, S.; Boote, E.J.; Casteel, S.W.; Fent, G.M.; Robertson, D.J.; Chandrasekhar, M.; Kannan, R.; Katti, K.V. Gum arabic as a phytochemical construct for the stabilization of gold nanoparticles: In vivo pharmacokinetics and X-ray-contrastimaging studies. Small, 2007, 3, 333-341.
21. Kannan, R.; Rahing, V.; Cutler, C.; Pandrapragada, R.; Katti, K.K.; Kattumuri, V.; Robertson, J.D.; Casteel, S.J.; Jurisson, S.; Smith, C.; Boote, E.; Katti, K.V. Nanocompatible chemistry toward fabrication of target-specific gold nanoparticles. J. Am. Chem. Soc., 2006, 128, 11342-11343.
22. Balogh, L.; Nigavekar, S.S.; Nair, B.M.; Lesniak, W.; Zhang, C.; Sung, L.Y.; Kariapper, M.S.; El-Jawahri, A.; Llanes, M.; Bolton, B.; Mamou, F.; Tan, W.; Hutson, A.; Minc, L.; Khan, M.K. Significant effect of size on the in vivo biodistribution of gold composite nanodevices in mouse tumor models. Nanomedicine, 2007, 3, 281-296.
23. Chanda, N.; Kan, P.; Watkinson, L.D.; Shukla, R.; Zambre, A.; Carmack, T.L.; Engelbrecht, H.; Lever, J.R.; Katti, K.; Fent, G.M.; Casteel, S.W.; Smith, C.J.; Miller, W.H.; Jurisson, S.; Boote, E.; Robertson, J.D.; Cutler, C.; Dobrovolskaia, M.; Kannan, R.; Katti, K.V. Radioactive gold nanoparticles in cancer therapy: Therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumorbearing mice. Nanomedicine, 2010, 6, 201-209.
24. Kannan, R.; Zambre, A.; Chanda, N.; Kulkarni, R.; Shukla, R.; Katti, K.; Upendran, A.; Cutler, C.; Boote, E.; Katti, K.V. Functionalized radioactive gold nanoparticles in tumor therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 2012, 4, 42-51.
25. Yi, L.; Wu, T.; Luo, W.; Zhou, W.; Wu, J. A non-invasive, rapid method to genotype late-onset alzheimer's disease-related apolipoprotein E gene polymorphisms. Neural. Regen. Res., 2014, 9, 69-75.
26. Huang, F.; Wang, J.; Qu, A.; Shen, L.; Liu, J.; Liu, J.; Zhang, Z.; An, Y.; Shi, L. Maintenance of amyloid- peptide homeostasis by artificial chaperones based on mixed-shell polymeric micelles. Angew. Chem. Int. Ed. Engl., 2014, 53, 8985-8990.
27. Sarvaiya, J.; Agrawal, Y.K. Chitosan as a suitable nanocarrier material for anti-Alzheimer drug delivery. Int. J. Biol. Macromol., 2014, 72C:454-465.
28. Pai, A.S.; Rubinstein, I.; Onyksel, H. PEGylated phospholipid nanomicelles interact with beta-amyloid((1-42)) and mitigate its beta-sheet formation, aggregation and neurotoxicity in vitro. Peptides, 2006, 27, 2858-66.
29. Zhang, C.; Zheng, X.; Wan, X.; Shao, X.; Liu, Q.; Zhang, Z.; Zhang, Q. The potential use of H102 peptide-loaded dualfunctional nanoparticles in the treatment of Alzheimer's disease. J. Control Release, 2014, 192, 317-324.
30. Kataoka, K.; Harada, A.; Nagasaki, Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug. Deliv. Rev., 2001, 47, 113-131.
31. Chonpathompikunlert, P.; Yoshitomi, T.; Han, J.; Toh, K.; Isoda, H.; Nagasaki, Y. Chemical nanotherapy: nitroxyl radicalcontaining nanoparticle protects neuroblastoma SH-SY5Y cells from Abeta-induced oxidative stress. Ther. Deliv. 2011, 2, 585-597.
32. de la Escosura-Muniz A, Plichta Z, Horak D, Merkoci A. Alzheimer's disease biomarkers detection in human samples by efficient capturing through porous magnetic microspheres and labelling with electrocatalytic gold nanoparticles. Biosens. Bioelectron., 2015, 67,162-169.
33. Bonanni, A.; Chua, C.K.; Zhao, G.; Sofer, Z.; Pumera, M. Inherently electroactive graphene oxide nanoplatelets as labels for single nucleotide polymorphism detection. ACS Nano., 2012, 6, 8546-8551.
34. Mancuso, C.; Bates, T.E.; Butterfield, D.A.; Calafato, S.; Cornelius, C.; De Lorenzo, A.; Dinkova Kostova, A.T.; Calabrese, V. Natural antioxidants in Alzheimers disease. Exp. Opin. Investig. Drugs, 2007, 16, 1921-1931.
35. Mukherjee, P.; Roy, M.; Mandal, B.P.; Dey, G.K.; Mukherjee, P.K.; Ghatak, J.; Tyagi, A.K.; Kale, S.P. Green synthesis of highly stabilized nanocrystalline silver particles by a non-pathogenic and agriculturally important fungus T. asperellum. Nanotechnology, 2008, 19, 075103.
36. Ai, J.; Biazar, E.; Jafarpour, M.; Montazeri, M.; Majdi, A.; Aminifard, S.; Zafari, M.; Akbari, H.R.; Rad, H.G. Nanotoxicology and nanoparticle safety in biomedical designs. Int. J. Nanomed., 2011, 6, 1117-1127.
37. Yoshitomi, T.; Suzuki, R.; Mamiya, T.; Matsui, H.; Hirayama, A.; Nagasaki, Y. pH sensitive radical-containing-nanoparticle (RNP) for the L-band-EPR imaging of low pH circumstances. Bioconjug. Chem., 2009, 20, 1792-1798.
38. Chonpathompikunlert, P.; Yoshitomi, T.; Han, J.; Isoda, H.; Nagasaki Y. The use of nitroxide radical-containing nanoparticles coupled with piperine to protect neuroblastoma SH-SY5Y cells from A-induced oxidative stress. Biomaterials, 2011, 32, 8605-8612.
39. Aruoma, O. I.; Bahorun, T.; Jen, L.S. Neuroprotection by bioactive components in medicinal and food plant extracts. Mutat. Res., 2003, 544, 203-215.
40. Behl, C.; Davis, J.B.; Lesley, R.; Schubert, D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell, 1994, 77, 817-827.
41. Obulesu, M.; Dowlathabad Muralidhara Rao, Bramhachari, P.V. Carotenoids and Alzheimers Disease: An insight into therapeutic role of retinoids in animal models. Neurochem. Int., 2011, 59, 535-541.
42. Lu, X.; Ji, C.; Xu, H.; Li, X.; Ding, H.; Ye, M.; Zhu, Z.; Ding, D.; Jiang, X.; Ding, X.; Guo, X. Resveratrol-loaded polymeric micelles protect cells from A-induced oxidative stress. Int. J. Pharm., 2009, 375, 89-96.
43. Picone, P.; Bondi, M.L.; Montana, G.; Bruno, A.; Pitarresi, G.; Giammona, G.; http://www.ncbi.nlm.nih.gov/pubmed?term=Di Carlo M%5BAuthor%5D&cauthor=true&cauthor-uid=19863373.
44. Di Carlo M. Ferulic acid inhibits oxidative stress and cell death induced by Ab oligomers: improved delivery by solid lipid nanoparticles. Free Radic. Res., 2009, 43, 1133-1145.
45. Adam, S.; Brian, G.; Paula, C.B.; Fountain, M.; Tan, J.; Shytle, R.D. Nanolipidic particles improve the bioavailability and asecretase inducing ability of epigallocatechin-3-gallate (EGCG) for the treatment of Alzheimers disease. Int. J. Pharm., 2010, 389, 207-212.
46. Chonpathompikunlert, P.; Han, J.; Toh, K.; Isoda, H.; Nagasaki, Y. TEMPOL protects human neuroblastoma SH-SY5Y cells against amyloid- induced cell toxicity. Eur. J. Pharmacol., 2011, 650, 544-549.
47. Marushima, A.; Suzuki, K.; Nagasaki, Y.; Yoshitomi, T.; Toh, K.; Tsurushima, H.; Hirayama, A.; Matsumura, A. Newly synthesized radical-containing nanoparticles (RNP) enhance neuroprotection after cerebral ischemia-reperfusion injury. Neurosurgery, 2011, 68, 1418-1426.
48. Li, Y.P.; Bushnell, A.F.; Lee, C.M.; Perlmutter, L.S.; Wong, S.K. Beta-amyloid induces apoptosis in human-derived neurotypic SHSY5Y cells. Brain. Res., 1996, 738, 196-204.
49. Guan, Z.Z.; Yu, W.F.; Nordberg, A. Dual effects of nicotine on oxidative stress and neuroprotection in PC12 cells. Neurochem. Int., 2003, 43, 243-249.
50. Yamada, J.; Yoshimura, S.; Yamakawa, H.; Sawada, M.; Nakagawa, M.; Hara, S.; Kaku, Y.; Iwama, T.; Naganawa, T.; Banno, Y.; Nakashima, S.; Sakai, N. Cell permeable ROS scavengers, Tiron and Tempol, rescue PC12 cell death caused by pyrogallol or hypoxia/reoxygenation. Neurosci. Res., 2003, 45, 1-8.
51. Thiemermann, C. Membrane-permeable radical scavengers (tempol) for shock, ischemia-reperfusion injury, and inflammation. Crit. Care Med., 2003, 31, S76-84.
52. Liang, Q.; Smith, A.D.; Pan, S.; Tyurin, V.A.; Kagan, V.E.; Hastings, T.G.; Schor, N.F. Neuroprotective effects of TEMPOL in central and peripheral nervous system models of Parkinsons disease. Biochem. Pharmacol., 2005, 70, 1371-1381.
53. Flohe, L. The glutathione peroxidase reaction: molecular basis of the antioxidant function of selenium in mammals. Curr. Top. Cell. Regul., 1985, 27, 473-478.
54. Chelikani, P.; Fita, I.; Loewen, P.C. Diversity of structures and properties among catalases. Cell. Mol. Life Sci., 2004, 61, 192-208.
55. Piyachaturawat, P.; Glinsukon, T.; Toskulkao, C. Acute and subacute toxicity of piperine in mice, rats and hamsters. Toxicol. Lett., 1983, 16, 351-359.
56. Unchern, S.; Saito, H.; Nishiyama, N. Selective cytotoxicity of piperine on cultured rat hippocampal neurons in comparison with cultured astrocytes: the possible involvement of lipid peroxidation. Biol. Pharm. Bull., 1997, 20, 958-961.
57. Lee, C.S.; Han, E.S.; Kim, Y.K. Piperine inhibition of 1-methyl-4- phenylpyridium induced mitochondrial dysfunction and cell death in PC12 cells. Eur. J. Pharmacol., 2006, 537, 37-44.
58. Krishna, M.C.; Russo, A.; Mitchell, J.B.; Goldstein, S.; Dafni, H.; Samuni, A. Do nitroxide antioxidants act as scavengers of O2- or as SOD mimics? J. Biol. Chem., 1996, 271, 26026-26031.
59. Samuni, A.; Mitchell, J.B.; DeGraff, W.; Krishna, C.M.; Samuni, U.; Russo, A. Nitroxide SOD-mimics: modes of action. Free. Radic. Res. Commun., 1991, 12-13, 187-194.
60. Mittal, R.; Gupta, R.L. In vitro antioxidant activity of piperine. Methods. Find. Exp. Clin. Pharmacol., 2000, 22, 271-274.
61. Ingkaninan, K.; Temkitthawon, P.; Chuenchom, K.; Yuyaem, T.; Thongnoi, W. Screening for acetylcholinesterase inhibitory activity in plants used in Thai traditional rejuvenating and neurotonic remedies. J. Ethonopharmacol., 2003, 89, 261-264.
62. Chonpathompikunlert, P.; Wattanathorn, J.; Muchimapura, S. Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimers disease. Food. Chem. Toxicol., 2010, 48, 798-802.
63. Hahn, S.M.; Lepinski, D.L.; DeLuca, A.M.; Mitchell, J.B.; Pellmar, T.C. Neurophysiological consequences of nitroxide antioxidants. Can. J. Physiol. Pharmacol., 1995, 73, 399-403.
64. Samuni, A.; Krishna, C.M.; Riesz, P.; Finkelstein, E.; Russo, A. A novel metal-free low molecular weight superoxide dismutase mimic. J. Biol. Chem., 1998, 263, 17921-17924.
65. Mitchell, J.B., Samuni, A., Krishna, M.C., DeGraff, W.G., Ahn, M.S., Samuni, U.; Russo A. Biologically active metal-independent superoxide dismutase mimics. Biochemistry, 1990, 29, 2802-2807.
66. Mitchell, J.B.; DeGraff, W.; Kaufman, D.; Krishna, M.C.; Samuni, A.; Finkelstein, E.; Ahn, M.S.; Hahn, S.M.; Gamson, J.; Russo, A. Inhibition of oxygen-dependent radiation induced damage by the nitroxide superoxide dismutase mimic, TEMPOL. Arch. Biochem. Biophys., 1991, 289, 62-70.
67. Hahn, S.M.; Mitchell, J.B.; Shacter, E. Tempol inhibits neutrophil and hydrogen peroxide-mediated DNA damage. Free Radic. Biol. Med., 1997, 23, 879-884.
68. Suy, S.; Mitchell, J.B.; Samuni, A.; Haimovitz-Friedman, A.; Kasid, U. Nitroxides TEMPOL and TEMPO induce divergent signal transduction pathways in MDA-MB 231 breast cancer cells. J. Biol. Chem., 1998, 273, 17871-17878.
69. Castagna, R.; Davis, P.A.; Vasu, V.T.; Soucek, K.; Cross, C.E.; Greci, L.; Valacchi. G. Nitroxide radical TEMPO reduces ozoneinduced chemokine IL-8 production in lung epithelial cells. Toxicol. In vitro., 2009, 23, 365-370.
70. Kocherginsky, N.; Swartz, H.M.; Seutjure, M. In: Nitroxide Spin Labels Reactions in Biology and Chemistry, Kocherginsky, N.; Swartz, H.M.; Eds. CRC Press, Boca Raton, FL, USA, 1995, 15-26.
71. Davda, J.; Labhasetwar, V. Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm., 2002, 233, 51-59.
72. Oishi, M.; Hayashi, H.; Iijima, M.; Nagasaki, Y. Endosomal release and intracellular delivery of anticancer drugs using pH-sensitive PEGylated nanogels. J. Mater. Chem., 2007, 17, 3720-3725.
73. Suy, S.; Mitchell, J.B.; Samuni, A.; Mueller, S.; Kasid, U. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice. Cancer, 2005, 103, 1302-1313.
74. Zhao, Q.L.; Fujiwara, Y.; Kondo, T. Mechanism of cell death induction by nitroxide and hyperthermia. Free Radic. Biol. Med., 2006, 40, 1131-1143.
75. Simonsen, U.; Christensen, F.H.; Buus, N.H. The effect of tempol on endothelium dependent vasodilatation and blood pressure. Pharmacol. Ther., 2009, 122, 109-124.
76. Krishna, M.C.; DeGraff, W.; Hankovszky, O.H.; Sar, C.P.; Kalai, T.; Jeko, J.; Russo, A.; Mitchell, J.B.; Hideg, K. Studies of structureeactivity relationship of nitroxide free radicals and their precursors as modifiers against oxidative damage. J. Med. Chem., 1998, 41, 3477-3492.
77. Chonpathompikunlert, P.; Yoshitomi, T.; Vong, L.B.; Imaizumi, N.; Ozaki, Y.; Nagasaki, Y. Recovery of Cognitive Dysfunction via Orally Administered Redox-Polymer Nanotherapeutics in SAMP8 Mice. PLoS One, 2015, 8, 10:e0126013.
78. Ray, B.; Chauhan, N.B.; Lahiri, D.K. Neuroprotective and neurorescue effects of a novel polymeric nanoparticle formulation of curcumin (NanoCurc) in the neuronal cell culture and animal model: implications for Alzheimer's disease. J. Alzheimers. Dis., 2011, 23, 61-77.
79. Lim, G.P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S.A.; Cole, G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci., 2001, 21, 8370-8377.
80. Reinke, A.A.; Gestwicki, J.E. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem. Biol. Drug. Des., 2007, 70, 206-215.
81. Durairajan, S.S.; Yuan, Q.; Xie, L.; Chan, W.S.; Kum, W.F.; Koo, I.; Liu, C.; Song, Y.; Huang, J.D.; Klein, W.L.; Li, M. Salvianolic acid B inhibits Abeta fibril formation and disaggregates preformed fibrils and protects against Abeta-induced cytotoxicty. Neurochem. Int., 2008, 52, 741-750.
82. Ansari, M.J.; Ahmad, S.; Kohli, K.; Ali, J.; Khar, R.K. Stabilityindicating HPTLC determination of curcumin in bulk drug and pharmaceutical formulations. J. Pharm. Biomed. Anal., 2005, 39, 132-138.
83. Ireson, C.R.; Jones, D.J.; Orr, S.; Coughtrie, M.W.; Boocock, D.J.; Williams, M.L.; Farmer, P.B.; Steward, W.P.; Gescher, A.J. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev. 2002, 11, 105-111.
84. Bisht, S.; Maitra, A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr. Drug. Discov. Technol., 2009, 6, 192-199.
85. Bisht, S.; Feldmann, G.; Soni, S.; Ravi, R.; Karikar, C.; Maitra, A.; Maitra, A. Polymeric nanoparticle-encapsulated curcumin (nanocurcumin): a novel strategy for human cancer therapy. J. Nanobiotechnology., 2007, 5, 3.
86. Bisht, S.; Mizuma, M.; Feldmann, G.; Ottenhof, N.A.; Hong, S.M.; Pramanik, D.; Chenna, V.; Karikari, C.; Sharma, R.; Goggins, M.G.; Rudek, M.A.; Ravi, R.; Maitra, A.; Maitra, A. Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in pre-clinical models of pancreatic cancer. Mol. Cancer. Ther., 2010, 9, 2255-2264.
87. Maragos, W.F.; Young, K.L.; Altman, C.S.; Pocernich, C.B.; Drake, J.; Butterfield, D.A.; Seif, I.; Holschneider, D.P.; Chen, K.; Shih, J.C. Striatal damage and oxidative stress induced by the mitochondrial toxin malonate are reduced in clorgyline-treated rats and MAO-A deficient mice. Neurochem. Res., 2004, 29, 741-746.
88. Kaminsky, Y.G.; Kosenko, E.A. Effects of amyloid-beta peptides on hydrogen peroxidemetabolizing enzymes in rat brain in vivo. Free Radic. Res., 2008, 42, 564-573.
89. Richter, C. Reactive oxygen and DNA damage in mitochondria. Mutat. Res., 1992, 275, 249-255.
90. Smith, M.A.; Perry, G.; Richey, P.L.; Perry, G.; Richey, P.L.; Sayre, L.M.; Anderson, V.E.; Beal, M.F.; Kowall, N. Oxidative damage in Alzheimer's. Nature, 1996, 382, 120-121.
91. Wang, Q.; Sun, A.Y.; Simonyi, A.; Jensen, M.D.; Shelat, P.B.; Rottinghaus, G.E.; MacDonald, R.S.; Miller, D.K.; Lubahn, D.E.; Weisman, G.A.; Sun, G.Y. Neuroprotective mechanisms of curcumin against cerebral ischemia-induced neuronal apoptosis and behavioral deficits. J. Neurosci. Res., 2005, 82, 138-148.
92. Cheng, K.K.; Yeung, C.F.; Ho, S.W.; Chow, S.F.; Chow, A.H.; Baum, L. Highly stabilized curcumin nanoparticles tested in an in vitro blood-brain barrier model and in Alzheimer's disease Tg2576 mice. AAPS J., 2013, 15, 324-336.
93. Pan, M.H.; Huang, T.M.; Lin, J.K. Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab. Dispos., 1999, 27, 486-494.
94. Begum, A.N.; Jones, M.R.; Lim, G.P.; Morihara, T.; Kim, P.; Heath, D.D.; Rock, C.L.; Pruitt, M.A.; Yang, F.; Hudspeth, B.; Hu, S.; Faull, K.F.; Teter, B.; Cole, G.M.; Frautschy, S.A. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimers disease. J. Pharmacol. Exp. Ther., 2008, 326, 196-208.
95. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: problems and promises. Mol. Pharm., 2007, 4, 807-818.
96. Doggui, S.; Sahni, J.K.; Arseneault, M.; Dao, L.; Ramassamy, C. Neuronal uptake and neuroprotective effect of curcumin-loaded PLGA nanoparticles on the human SK-N-SH cell line. J. Alzheimers. Dis., 2012, 30, 377-392.
97. Obulesu, M.; Dowlathabad Muralidhara Rao,; Keshav P. Raichurkar.; N.M. Shamasundar. First MRI studies on aluminium maltolate treated aged New Zealand rabbit. Psychogeriatrics, 2015, Epub ahead of print].
98. Wadghiri, Y.Z.; Li, J.; Wang, J.; Hoang, D.M.; Sun, Y.; Xu, H.; Tsui, W.; Li, Y.; Boutajangout, A.; Wang, A.; de Leon, M.; Wisniewski, T. Detection of amyloid plaques targeted by bifunctional USPIO in Alzheimer's disease transgenic mice using magnetic resonance microimaging. PLoS One, 2013, 8, e57097.
99. Sillerud, L.O.; Solberg, N.O.; Chamberlain, R.; Orlando, R.A.; Heidrich, J.E.; Brown, D.C.; Brady, C.I.; Van der Jagt, T.A.; Garwood, M.; Van der Jagt, D.L. SPION-enhanced magnetic resonance imaging of Alzheimer's disease plaques in A-PP/PS-1 transgenic mouse brain. J. Alzheimers. Dis., 2013, 34, 349-365.
100. Kim, J.H.; Ha, T.L.; Im, G.H.; Yang, J.; Seo, S.W.; Lee, I.S.; Lee, J.H. Magnetic resonance imaging of amyloid plaques using hollow manganese oxide nanoparticles conjugated with antibody a-1-40 in a transgenic mouse model. Neuroreport., 2013, 24, 16-21.
101. Tanifum, E.A.; Dasgupta, I.; Srivastava, M.; Bhavan e, R.C.; Sun, L.; Berridge, J.; Pourgarzham, H.; Kamath, R.; Espinosa, G.; Cook, S.C.; Eriksen, J.L.; Annapragada, A. Intravenous delivery of tar geted liposomes to amyloid- pathology in APP/PSEN1 transgenic mice. PLoS One, 2012; 7, e48515.
102. Orlando, A.; Re, F.; Sesana, S.; Rivolta, I.; Panariti, A.; Brambilla, D.; Nicolas, J.; Couvreur, P.; Andrieux, K.; Masserini, M.; Cazzaniga, E. Effect of nanoparticles binding-amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages. Int. J. Nanomedicine, 2013, 8, 1335-1347.
103. Liu, L.; Zhao, F.; Ma, F.; Zhang, L.; Yang, S.; Xia, N. Electrochemical detection of-amyloid peptides on electrode covered with N-terminus-specific antibody based on electrocatalytic O2 reduction by A-(1-16)-heme-modified gold nanoparticles. Biosens. Bioelectron., 2013, 49C, 231-235.
104. Li, M.; Xu, C.; Wu, L.; Ren, J.; Wang, E.; Qu, X. Self-Assembled Peptide-Polyoxometalate Hybrid Nanospheres: Two in One Enhances Targeted Inhibition of Amyloid-Peptide Aggregation Associated with Alzheimer's Disease. Small, 2013, 9, 3455-3461.
105. Md, S.; Ali, M.; Baboota, S.; Sahni, J.K.; Bhatnagar, A.; Ali, J. Preparation, characterization, in vivo biodistribution and pharmacokinetic studies of donepezil-loaded PLGA nanoparticles for brain targeting. Drug. Dev. Ind. Pharm., 2013, 40, 278-287.
106. Liu, D.; Chen, W.; Tian, Y.; He, S.; Zheng, W.; Sun, J.; Wang, Z.; Jiang, X. A highly sensitive gold-nanoparticle-based assay for acetylcholinesterase in cerebrospinal fluid of transgenic mice with Alzheimer's disease. Adv. Healthc. Mater., 2012, 1, 90-95.
107. Bernardi, A.; Frozza, R.L.; Meneghetti, A.; Hoppe, J.B.; Battastini, A.M.; Pohlmann, A.R.; Guterres, S.S.; Salbego, C.G. Indomethacin- loaded lipid-core nanocapsules reduce the damage triggered by A-1-42 in Alzheimer's disease models. Int. J. Nanomedicine, 2012, 7, 4927-4942.
108. Liu, G.; Men, P.; Perry, G.; Smith, M.A. Nanoparticle and iron chelators as a potential novel Alzheimer therapy. Methods Mol. Biol., 2010, 610, 123-144.
109. McLachlan, D.R.; Kruck, T.P.; Lukiw, W.J.; Krishnan, S.S. Would decreased aluminum ingestion reduce the incidence of Alzheimers disease? CMAJ., 1991, 145, 793-804.
110. Loske, C.; Gerdemann, A.; Schepl, W.; Wycislo, M.; Schinzel, R.; Palm, D.; Riederer, P.; Munch, G. Transition metal-mediated glycoxidation accelerates cross-linking of beta-amyloid peptide. Eur. J. Biochem., 2000, 267, 4171-4178.
111. Ritchie, C.W.; Bush, A.I.; Mackinnon, A.; Macfarlane, S.; Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q.X.; Tammer, A.; Carrington, D.; Mavros, C.; Volitakis, I.; Xilinas, M.; Ames, D.; Davis, S.; Beyreuther, K.; Tanzi, R.E.; Masters, C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch. Neurol., 2003, 60, 1685-1691.
112. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv. Drug Deliv. Rev., 2001, 47, 65-81.
113. Kreuter, J.; Shamenkov, D.; Petrov, V.; Ramge, P.; Cychutek, K.; Koch-Brandt, C.; Alyautdin, R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target., 2002, 10, 317-325.
114. Wilson, B.; Samanta, M.K.; Santhi, K.; Kumar, K.P.; Paramakrishnan, N.; Suresh, B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimers disease. Brain Res., 2008, 1200, 159-168.
115. Liu, G.; Men, P.; Harris, P.L.; Rolston, R.K.; Perry, G.; Smith, M.A. Nanoparticle iron chelators: A new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett., 2006, 406, 189-193.
116. Liu, G.; Men, P.; Perry, G.; Smith, M.A. In: Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. Prog. Brain Res. 2009, 180, 97-108.
117. Geng, J.; Li, M.; Wu, L.; Chen, C.; Qu, X. Mesoporous silica nanoparticle-based H2O2 responsive controlled-release system used for Alzheimer's disease treatment. Adv. Healthc. Mater., 2012, 1, 332-336.
118. Bonda, D.J.; Liu, G.; Men, P.; Perry, G.; Smith, M.A.; Zhu, X. Nanoparticle delivery of transition-metal chelators to the brain: Oxidative stress will never see it coming! CNS Neurol. Disord. Drug Target., 2012, 11, 81-85.
119. Popovic N, Brundin P. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases. Int. J. Pharm., 2006, 314, 120-126.
120. Imperatore, R.; Carotenuto, G.; Di Grazia, M.A.; Ferrandino, I.; Palomba, L.; Mariotti, R.; Vitale, E.; De Nicola, S.; Longo, A.; Cristino, L. Imidazole-stabilized gold nanoparticles induce neuronal apoptosis: An in vitro and in vivo study. J. Biomed. Mater. Res. A., 2015, 103(4), 1436-1446.
121. Denora, N.; Trapani, A.; Laquintana, V.; Lopedota, A.; Trapani, G. Recent advan ces in medicinal chemistry and pharmaceutical technology- strategies for drug delivery to the brain. Curr. Top. Med. Chem., 2009, 9, 182-196.